JP2024515560A5 - - Google Patents

Info

Publication number
JP2024515560A5
JP2024515560A5 JP2023561644A JP2023561644A JP2024515560A5 JP 2024515560 A5 JP2024515560 A5 JP 2024515560A5 JP 2023561644 A JP2023561644 A JP 2023561644A JP 2023561644 A JP2023561644 A JP 2023561644A JP 2024515560 A5 JP2024515560 A5 JP 2024515560A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
variable region
chain variable
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561644A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515560A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023961 external-priority patent/WO2022217019A1/en
Publication of JP2024515560A publication Critical patent/JP2024515560A/ja
Publication of JP2024515560A5 publication Critical patent/JP2024515560A5/ja
Pending legal-status Critical Current

Links

JP2023561644A 2021-04-09 2022-04-08 Ilt4に対する抗体、二重特異性の抗ilt4/pd-l1抗体、およびそれらの使用方法 Pending JP2024515560A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163172997P 2021-04-09 2021-04-09
US63/172,997 2021-04-09
PCT/US2022/023961 WO2022217019A1 (en) 2021-04-09 2022-04-08 Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof

Publications (2)

Publication Number Publication Date
JP2024515560A JP2024515560A (ja) 2024-04-10
JP2024515560A5 true JP2024515560A5 (https=) 2025-04-03

Family

ID=81449213

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561644A Pending JP2024515560A (ja) 2021-04-09 2022-04-08 Ilt4に対する抗体、二重特異性の抗ilt4/pd-l1抗体、およびそれらの使用方法

Country Status (11)

Country Link
US (1) US20240417459A1 (https=)
EP (1) EP4320159A1 (https=)
JP (1) JP2024515560A (https=)
KR (1) KR20240006541A (https=)
CN (1) CN117545773A (https=)
AU (1) AU2022253269A1 (https=)
BR (1) BR112023020303A2 (https=)
CA (1) CA3214853A1 (https=)
IL (1) IL307519A (https=)
MX (1) MX2023011788A (https=)
WO (1) WO2022217019A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023077521A1 (en) * 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2024120526A1 (zh) * 2022-12-09 2024-06-13 诺纳生物(苏州)有限公司 抗ilt4抗体及其制备方法和应用
WO2025133389A1 (en) * 2023-12-22 2025-06-26 Numab Therapeutics AG Antibody binding domains having specificity for lilrb2
EP4574844A1 (en) * 2023-12-22 2025-06-25 Numab Therapeutics AG Multispecific antibodies having specificity for cd47 and pdl1
WO2026003224A2 (en) 2024-06-26 2026-01-02 Iomx Therapeutics Ag Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990006951A1 (en) 1988-12-16 1990-06-28 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
EP0414374B1 (en) 1989-07-25 1997-10-08 Smithkline Biologicals S.A. Novel antigens and methods for their preparation
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
JP3958360B2 (ja) 1995-02-24 2007-08-15 キャンタブ ファーマシューティカルズ リサーチ リミティド 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
EP0998557A2 (en) 1997-07-21 2000-05-10 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
AU2001255196A1 (en) 2000-03-29 2001-10-08 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
CN101888856B (zh) 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体
WO2016111947A2 (en) * 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
TWI796329B (zh) * 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗-ilt4抗體及抗原結合片段
CA3097369A1 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
CN113056483B (zh) * 2018-07-09 2025-08-01 戊瑞治疗有限公司 结合到ilt4的抗体
US20210301020A1 (en) * 2018-07-24 2021-09-30 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors

Similar Documents

Publication Publication Date Title
JP2024515560A5 (https=)
JP6606505B2 (ja) 抗SIRPα抗体および二重特異性マクロファージ増強抗体
JP2019524693A5 (https=)
JP2020510422A5 (https=)
JP2021508469A5 (https=)
JP2021510710A5 (https=)
JP2022515318A5 (https=)
JP2023509448A5 (https=)
JP2021521793A5 (https=)
JP2020501531A5 (https=)
JP2021510521A5 (https=)
WO2018147245A1 (ja) 抗gprc5d抗体及び該抗体を含む分子
JP2021528973A5 (https=)
JP2017535257A5 (https=)
JP2013527761A5 (https=)
CA3196809A1 (en) Combination treatment
JP2021508707A5 (https=)
JP2023540526A5 (https=)
JP2022533538A5 (https=)
JP2023549537A5 (https=)
JP7851303B2 (ja) ヒトcd3イプシロンに結合する新規なヒト抗体
JP2019512207A5 (https=)
JP2021520201A5 (https=)
JP2024001073A5 (https=)
JP2020515277A5 (https=)